NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Monday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets decreased their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

Shares of NBY stock opened at $0.81 on Monday. The firm has a market cap of $3.98 million, a PE ratio of -0.02 and a beta of 0.65. The company has a 50-day moving average of $0.62 and a two-hundred day moving average of $0.75. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.32). NovaBay Pharmaceuticals had a negative net margin of 102.72% and a negative return on equity of 7,293.78%. The business had revenue of $2.44 million during the quarter, compared to analysts’ expectations of $2.50 million. Sell-side analysts anticipate that NovaBay Pharmaceuticals will post -3.26 EPS for the current fiscal year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.